Piramal Pharma Limited Announces Results for Q2 and H1 FY25
MUMBAI, Oct. 23, 2024 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30th September 2024.
Consolidated Financial Highlights
(in ₹ Cr. or as stated)
Particulars
Q2FY25
Q2FY24
YoY Growth
H1FY25
H1FY24
YoY Growth
Revenue from Operations
2,242
1,911
17 %
4,193
3,660
15 %
CDMO
1,324
1,068
24 %
2,381
1,967
21 %
CHG
643
589
9 %
1,274
1,206
6 %
ICH
277
256
8 %
541
495
9 %
EBITDA
403
315
28 %
627
485
29 %
EBITDA Margin
18 %
16 %
-
15 %
13 %
-
Share of Net Profit of Associates
17
19
(10) %
40
33
18 %
PAT
23
5
350 %
(66)
(94)
NM
PAT Margin
1 %
0 %
-
(2) %
(3) %
-
Key Highlights for Q2FY25
Revenue from Operations grew by 17% YoY, primarily driven by robust growth in CDMO business
EBITDA grew by 28% YoY with EBITDA margin of 18%, a YoY improvement of about 150bps, driven by operating leverage, cost optimization initiatives and superior revenue mix
Released our FY2024 Sustainability Report. The report follows GRI standards and is aligned with SASSB and UNGC frameworks. It also highlights our commitment to reduce our GHG1 emissions in-line with SBTi's2 1.5o decarbonization pathway
Nandini Piramal, Chairperson, Piramal Pharma Limited said, "We continue our momentum of delivering healthy revenue growth accompanied by YoY EBITDA margin expansion. This has been primarily driven by consistent growth in our CDMO business which has witnessed a good pick-up in innovation related work and on-patent commercial revenues. To sustain this growth momentum and to capitalize on rising demand for sterile fill-finish capabilities, we have announced a US$80Mn expansion plan at our Lexington facility which is expected to get complete by end FY27. In our CHG business, we are witnessing steady volume growth in Inhalation Anesthesia products in the US and Emerging Markets. In our ICH business, we continue to see a robust growth in our power brands and e-commerce sales.
During the quarter, we released our Sustainability Report for FY24 under the theme, 'Building Resilience for a Sustainable Tomorrow', highlighting our progress on the sustainability initiatives.
Over the long term, we remain committed to achieving our financial goals of US$2 bn revenue with 25% EBITDA margin and 1x net debt / EBITDA by FY30."
1. Green House Gas; 2. Science Based Target initiative
Key Business Highlights for Q2 and H1 FY25
Contract Development and Manufacturing Organization (CDMO):
- Market ...
